insights_auto
Why is ABVX down 17.21%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
€63.00
arrow_downward
-17.21%(-13.10) 1D
ኖቬም 20, 5:38:58 ከሰዓት ጂ ኤም ቲ+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€74.50
High
€74.50
Low
€59.30
Mkt. cap
5.57 ቢ
Avg. vol.
112.96 ሺ
Volume
842.42 ሺ
52-wk high
€139.00
52-wk low
€59.30
EPS
-€5.20
Shares outstanding
87.55 ሚ
No. of employees
98
Open
€74.50
High
€74.50
Low
€59.30
Mkt. cap
5.57 ቢ
Avg. vol.
112.96 ሺ
Volume
842.42 ሺ
52-wk high
€139.00
52-wk low
€59.30
EPS
-€5.20
Shares outstanding
87.55 ሚ
No. of employees
98
News stories
From web sources and news partners
AP News
·
ከ2 ሰዓቶች በፊት
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
The Motley Fool
·
ከ1 ሰዓት በፊት
Report: Goldman Sachs Predicts the S&P 500 Will Gain 26% in 12 Months
WSJ
·
ከ16 ሰዓቶች በፊት
S&P 500 Flirts With Correction
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded4 ዲሴም 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com